Jamie Oliver, Pharm. D.
President & Chief Executive OfficerDr. Oliver has more than 28 years of clinical research experience in both academia and the pharmaceutical industry. He has provided overall strategic and operational direction in biotechnology drug development for clinical, regulatory, research and development, quality assurance, and manufacturing. Most recently he has provided strategic development solutions and due diligence to mid- to large sized pharmaceutical companies in the US and Asia. Dr. Oliver has experience with both Drug (CDER) and Biologic (CBER) divisions at the FDA, successfully filing 28 INDs and authoring multiple NDA submissions. He has participated in meetings with more than half of the review Divisions of the FDA and has represented and attended FDA meetings for all types of PDUFA meetings. His academic tenure includes adjunct clinical faculty collaboration with Emory University, Mercer University, and the Centers for Disease Control and Prevention Hospital Infections Branch. Dr. Oliver received his bachelor’s degree and Doctorate in Pharmacy from Mercer University in Atlanta.

Wei Chen, Ph.D.
Chief Scientific Officer

Dr. Chen has more than 25 years of experience in managing product development and cGMP manufacturing of biologic drugs, including recombinant protein-based therapeutics such as interferon, growth hormone, anti-infectious agents; monoclonal antibodies; DNA vectors; vaccines; and anti-cancer therapeutics. Prior to joining Phage, Dr. Chen was the CTO of Symbigene, a biologic delivery technology company for biosimilars/biobetters, VP of product development and manufacturing at CoRautus/Baxter for Clotting Factor VIII and Adenoviral expression vectors. Prior to that, Dr. Chen held product development and cGMP manufacturing positions at Bristol-Myers Squibb, Centocor/J&J, Immunomedics, and BioReliance. Dr. Chen received Ph.D. in Bioreaction Engineering/Applied Microbiology from Nagoya University, Japan and did postdoc research in Bacteriophages at Yale Medical School and UCLA.

Thomas J. Stegmann, M.D., Ph.D.
Chief Medical Officer

Dr. Thomas J. Stegmann is a Cardiothoracic Surgeon and Professor of Surgery who, for over twenty years, served as Director of the Department of Thoracic and Cardiovascular Surgery at the Fulda Medical Center in Fulda, Germany. Dr. Stegmann is known internationally for his pioneer work in inducing angiogenesis (the growth of new vessels) in the heart. He has published and lectured widely in this area. His landmark clinical trials with FGF in inducing angiogenesis in the heart have been published in prestigious medical journals including Circulation and the Journal of Cardiac and Vascular Regeneration.

Dr. Stegmann received his medical degree (summa cum laude) from Heidelberg University, Heidelberg, Germany and completed a doctoral thesis as part of that degree. The thesis, entitled “Content of Catecholamines and Change in Enzyme-activities of the Cardiac Muscle in Experimentally Hypertrophied Hearts” was awarded the prize for “Best Dissertation.”